531210 COLINZ

Colinz Laboratories Share Price

 

 

Start SIP in COLINZ

Start SIP
Colinz Laboratories live price: ₹41.16. It opened at ₹41 vs previous close ₹43; intraday high/low: ₹42/₹41. The 50 & 200 DMA stand at ₹50.48/₹49.60.

Colinz Laboratories Performance

  • Low
  • ₹41
  • High
  • ₹42
  • 52 Week Low
  • ₹36
  • 52 Week High
  • ₹89
  • Open Price₹41
  • Previous Close₹43
  • Volume645
  • 50 DMA₹50.48
  • 100 DMA₹49.85
  • 200 DMA₹49.60

Investment Returns

  • Over 1 Month -19.79%
  • Over 3 Month -9.78%
  • Over 6 Month + 2.12%
  • Over 1 Year -27.45%

Smart Investing Starts Here Start SIP with Colinz Laboratories for Steady Growth!

Invest Now

Colinz Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21
  • PEG Ratio
  • 8.8
  • Market Cap Cr
  • 10
  • P/B Ratio
  • 1
  • Average True Range
  • 3.45
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.4
  • RSI
  • 37.58
  • MFI
  • 46.43

Colinz Laboratories Financials

Colinz Laboratories Technicals

EMA & SMA

Current Price
₹41.16
-2.09 (-4.83%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹47.45
  • 50 Day
  • ₹50.48
  • 100 Day
  • ₹49.85
  • 200 Day
  • ₹49.60

Resistance and Support

43.41 Pivot Speed
  • R3 49.62
  • R2 47.60
  • R1 45.43
  • S1 41.24
  • S2 39.22
  • S3 37.05

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Colinz Laboratories has an operating revenue of Rs. 5.84 Cr. on a trailing 12-month basis. An annual revenue de-growth of -6% needs improvement, Pre-tax margin of 9% is okay, ROE of 5% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 68 which is a FAIR score but needs to improve its earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 26 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Colinz Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-24 Quarterly Results
2026-01-17 Others
2025-11-27 Others Inter-alia to approve appointment of Ms. Falguni Kumawat as the Company Secretary and Compliance Officer of the Company and Key Managerial Personnel of the Company.
2025-11-11 Others Inter-alia, to approve appointment of Smt. Vijaya Mani (DIN 11363910) as Additional (Non- Executive) Director of the Company.
2025-11-03 Quarterly Results

Colinz Laboratories F&O

Colinz Laboratories Shareholding Pattern

66%
31.01%
2.99%

Colinz Laboratories FAQs

Colinz Laboratories share price is ₹41 As on 13 March, 2026 | 13:29

The Market Cap of Colinz Laboratories is ₹10.4 Cr As on 13 March, 2026 | 13:29

The P/E ratio of Colinz Laboratories is 21 As on 13 March, 2026 | 13:29

The PB ratio of Colinz Laboratories is 1 As on 13 March, 2026 | 13:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23